Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Lunch & Poster Display session

23P - Immunological signature meta-analysis across lung cancer cohorts within the NanoString Clinical Transcriptional Atlas Group (CTAG) associated with patient outcome and history


12 Dec 2019


Lunch & Poster Display session


Nina Radosevic-Robin


Annals of Oncology (2019) 30 (suppl_11): xi1-xi11. 10.1093/annonc/mdz447


N. Radosevic-Robin1, J. Reeves2, K. Leroy3, M. Duruisseaux4, P. Morel5, M. Bhagat6, F. Penault-Llorca1, D. Damotte3, F. Goldwasser3, A. Brindel7, M. Cumberbatch6, S. Ong2, J. Lopez8, S. Warren2

Author affiliations

  • 1 Department Of Pathology, University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, 63011 - Clermont-Ferrand/FR
  • 2 Translational Science, NanoString Technologies, 98109 - Seattle/US
  • 3 Department Of Genetic And Molecular Biology, University Paris Descartes APHP, Hospital Cochin, 75006 - Paris/FR
  • 4 Oncology, Institut de Cancérologie des Hospices Civiles de Lyon, 69500 - Bron/FR
  • 5 Medical Affairs, NanoString Technologies, 98109 - Seattle/US
  • 6 R&d, Tristar Technologies, 20006 - Washington DC/US
  • 7 Respiratory Department, CHRU Nancy, 69677 - Vandoeuvre-les-Nancy/FR
  • 8 Biochemistry Department, Hospices Civiles de Lyon de Sud, 69310 - Pierre-Bénite/FR


Abstract 23P


With the approval of anti-PD1 blocking antibodies in a growing number of indications, understanding the mechanisms responsible for potentiating response to these agents has been a critical avenue of research. However, most studies rely on the use of single cohorts and are relatively limited in their scope, thus limited their utility.


We created a consortium of investigators who share clinical and accompanying transcriptional data collected on the NanoString® nCounter® platform from patients treated with single agent immunotherapy to facilitate biomarker research. In this study, we apply a meta-analysis to a combined cohort of 4 lung cancer studies (n = 150) to identify transcriptional correlates of response to identify patients who are likely to experience clinical benefit.


RNA was profiled with the NanoString IO360 and IO360 beta gene expression panels, and 43 signatures that describe facets of the immune response, tumor biology, and the tumor microenvironment were calculated. Included in these signatures is the Tumor Inflammation Signature (TIS), an investigational 18 gene signature of a suppressed adaptive immune response which enriches for clinical response to pembrolizumab. These signatures, as well as genes of interest identified in a given cohort, were compared to objective response, overall survival, or progression free survival across the cohorts. We confirm previously reported association of TIS with patient outcome and identify immune cell subsets that are also associated with response. In addition, we examine differences between patients with distinct mutational backgrounds, smoking histories, or histological classifications, as well as differences attributable to biopsy location.


This multi-cohort study allows for the development of multi-variate predictors of response to anti-PD1 monotherapy using a single research assay to transcriptionally profile the tumors. We can generate robust predictions from real-world cohorts, which may lead to the development of improved diagnostic assays to guide treatment decisions.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

NanoString Technologies.


NanoString Technologies.


N. Radosevic-Robin: Research grant / Funding (institution): NanoString Technologies. J. Reeves: Full / Part-time employment: NanoString Technologies. K. Leroy: Research grant / Funding (self): NanoString Technologies. M. Duruisseaux: Research grant / Funding (self): NanoString Technologies. P. Morel: Full / Part-time employment: NanoString Technologies. M. Bhagat: Research grant / Funding (institution): NanoString Technologies. F. Penault-Llorca: Advisory / Consultancy, Research grant / Funding (institution): NanoString Technologies. D. Damotte: Research grant / Funding (institution): NanoString Technologies. F. Goldwasser: Research grant / Funding (institution): NanoString Technologies. A. Brindel: Research grant / Funding (institution): NanoString Technologies. M. Cumberbatch: Research grant / Funding (institution): NanoString Technologies. S. Ong: Full / Part-time employment: NanoString Technologies. J. Lopez: Research grant / Funding (institution): NanoString Technologies. S. Warren: Full / Part-time employment: NanoString Technologies.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.